183 related articles for article (PubMed ID: 36333718)
21. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
[TBL] [Abstract][Full Text] [Related]
22. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
23. A case study of a long-term glioblastoma survivor with unmethylated
Jue TR; Olafson LR; Siddell AH; Rapkins RW; Ng B; Yin JXM; Lu VM; Chung SA; Whittaker SP; Davies M; Fairhall JM; Hovey EJ; McDonald KL
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160353
[TBL] [Abstract][Full Text] [Related]
24. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
[TBL] [Abstract][Full Text] [Related]
25. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
26. Recurrent glioblastoma multiforme: a review of natural history and management options.
Hou LC; Veeravagu A; Hsu AR; Tse VC
Neurosurg Focus; 2006 Apr; 20(4):E5. PubMed ID: 16709036
[TBL] [Abstract][Full Text] [Related]
27. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
Lim-Fat MJ; Youssef GC; Touat M; Iorgulescu JB; Whorral S; Allen M; Rahman R; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Batchelor TT; Arnaout O; Peruzzi PP; Chiocca EA; Reardon DA; Meredith D; Santagata S; Beroukhim R; Bi WL; Ligon KL; Wen PY
Neuro Oncol; 2022 Jul; 24(7):1140-1149. PubMed ID: 34878541
[TBL] [Abstract][Full Text] [Related]
29. The SAFE-trial: Safe surgery for glioblastoma multiforme: Awake craniotomy versus surgery under general anesthesia. Study protocol for a multicenter prospective randomized controlled trial.
Gerritsen JKW; Klimek M; Dirven CMF; Hoop EO; Wagemakers M; Rutten GJM; Kloet A; Hallaert GG; Vincent AJPE
Contemp Clin Trials; 2020 Jan; 88():105876. PubMed ID: 31676314
[TBL] [Abstract][Full Text] [Related]
30. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
31. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme.
Mirza FA; Shamim MS
J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361
[TBL] [Abstract][Full Text] [Related]
32. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
Zeitlberger AM; Putora PM; Hofer S; Schucht P; Migliorini D; Hottinger AF; Roelcke U; Läubli H; Spina P; Bozinov O; Weller M; Neidert MC; Hundsberger T
J Neurooncol; 2022 Jul; 158(3):359-367. PubMed ID: 35486306
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib in glioblastoma recurrence: A case report.
Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
[TBL] [Abstract][Full Text] [Related]
34. Treating recurrent glioblastoma: an update.
Kamiya-Matsuoka C; Gilbert MR
CNS Oncol; 2015; 4(2):91-104. PubMed ID: 25768333
[TBL] [Abstract][Full Text] [Related]
35. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
[TBL] [Abstract][Full Text] [Related]
36. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
37. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
38. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
[TBL] [Abstract][Full Text] [Related]
39. Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.
Nduom EK; Gephart MH; Chheda MG; Suva ML; Amankulor N; Battiste JD; Campian JL; Dacey RG; Das S; Fecci PE; Hadjipanayis CG; Hoang KB; Jalali A; Orringer D; Patel AJ; Placantonakis D; Rodriguez A; Yang I; Yu JS; Zipfel GJ; Dunn GP; Leuthardt EC; Kim AH
Neurosurgery; 2021 Jun; 89(1):129-132. PubMed ID: 33862619
[TBL] [Abstract][Full Text] [Related]
40. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]